Jump to content
World's Largest Herpes Support Group
Sign in to follow this  
solvingtheproblem

AHRQ Awards $4.5 million to Create Clinical Preventive Services Research Centers

Recommended Posts

solvingtheproblem

I just received this notice in an email from the CDC; not sure what to make of it, but it seems these centers might be able to influence the inclusion of HSV into full STD screening...especially since the most recent version of the CDC's STD Guidelines recommend that HSV serologic testing for people requesting STD testing. Any thoughts as to best utilize this opportunity?

------------------------------------------------------------------------------------

AHRQ Awards $4.5 million to Create Clinical Preventive Services Research Centers

The Agency for Healthcare Research and Quality (AHRQ) awarded three-year grants totaling $4.5 million to support research in three centers that will focus on improving clinical preventive services and practices such as screening, counseling and use of preventive medications for patients. The project will be led by three universities and includes a separate award for coordination and evaluation of the research.

The innovation for these centers is made possible through the Prevention and Public Health Fund, part of the Affordable Care Act, and is designed to expand and sustain the necessary capacity to prevent disease, detect it early and manage conditions before they become severe. States and communities are also funded to acquire the resources they need to promote healthy living. Through this initiative, the National Prevention Strategy was established to bring together leaders across the government to establish priorities for the new frontiers of knowledge and implementation of preventive health.

Consistent with the National Prevention Strategy of the U.S. Department of Health and Human Services interest and energy, AHRQ planned a significant research effort to establish the Research Centers for Excellence in Clinical Preventive Services that are located in Chicago, Chapel Hill, N.C., and Aurora, Colo. The centers will serve to advance the national research agenda in clinical preventive services in three specific areas:

Health equity – to learn more about how to reduce disparities in the use of clinical preventives services.

Patient safety – to better the understanding of risks and harms associated with clinical preventives services.

Health systems implementation – to study how primary care practices, public health resources and the larger health care system can improve the delivery of evidence-based clinical preventive services.

“We know that preventing disease is the key to improving the health of all Americans, but we also know that there are some very serious gaps in clinical preventive services research,” said AHRQ Director Carolyn M. Clancy, M.D. “AHRQ’s investment in these new research centers will help us find ways to enhance the quality of clinical preventive services.

Each center will conduct research projects during the three-year grant, including pilot and exploratory projects affecting children, the elderly, minorities, those with disabilities and those who receive health care in rural and inner city settings.

The centers will be located at the following institutions:

Northwestern University, Chicago - Award: $1.4 million. The Center for Advancing Equity in Clinical Preventive Services will develop and test interventions to achieve equity in clinical preventive services by focusing on health literacy, health communication, quality improvement methods and health information technology.

University of North Carolina (UNC) at Chapel Hill – Award: $1.5 million. The UNC Research Center for Excellence in Clinical Preventive Services will focus on research to improve patient safety and reduce potential harms to patients by improving the appropriate use of clinical preventive services in primary health care practices.

University of Colorado, Anschutz Medical Campus – Award: $1.5 million. The Center for Excellence in Research in Implementation Science and Prevention will involve primary care and public health experts to conduct research on how to increase use of preventive health services within primary health care settings while meeting national public health goals.

In addition, Abt Associates, Cambridge, Mass., has received an award to help coordinate and evaluate the research being conducted at the three centers.

More information about AHRQ’s Center for Primary Care, Prevention, and Clinical Partnerships, is available at http://www.ahrq.gov/about/cp3/. For inquiries related to this press release, please contact Janine Payne at 301-427-1870, or Rachel Weinstein at 301-427-1853.

Share this post


Link to post
Share on other sites
Number7

News on Herpes coldsores from Science Daily-

Specific gene linked to cold sore susceptibility, study finds

Posted: 28 Oct 2011 05:27 AM PDT

Researchers have identified a human chromosome containing a specific gene associated with susceptibility to herpes simplex labialis, the common cold sore. The study looks at how several genes may affect the severity of symptoms and frequency of this common infection. The findings, if confirmed, could have implications for the development of new drugs to treat outbreaks.9CApBwwzc-g?utm_source=feedburner&utm_medium=email

Share this post


Link to post
Share on other sites
Number7
News on Herpes coldsores from Science Daily-

Specific gene linked to cold sore susceptibility, study finds

Posted: 28 Oct 2011 05:27 AM PDT

Researchers have identified a human chromosome containing a specific gene associated with susceptibility to herpes simplex labialis, the common cold sore. The study looks at how several genes may affect the severity of symptoms and frequency of this common infection. The findings, if confirmed, could have implications for the development of new drugs to treat outbreaks.9CApBwwzc-g?utm_source=feedburner&utm_medium=email

Oops - already posted in "Technical Discussion" - see comments there

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

Advertisement

Try a Lysine supplement for cold sores

  • The Hive is Thriving!

    • Total Topics
      67,965
    • Total Posts
      453,209
  • Posts

    • WilsoInAus
      No it’s not a fact at all. How can it be a correlation if it happens no more than chance? Remember 70-80% of people using PW have herpes.
    • BeautyLover321
      Hello! Thanks so much for your reply. I was told (and believe) I have HSV 2. They told me that on the phone; it was confirmed through swab. I have never taken a blood test or been tested for it otherwise. I've read mixed reviews about HSV1 providing protection-- because some studies seem to allude that it does. If this is true- it makes sense because I never had chicken pox or HSV1 in my entire life so I think it explains why I caught HSV2 from a one night experience (just my luck and just my own theory) Although I still experience twitching in my body -- I feel happy that the valtrex every other day suppresses it. But I do wonder, because I'm experiencing such reduced symptoms; if my shedding is reduced too. I doubt it but just a thought.  Anyways - I can live with condoms but I don't want to.. so I'm hoping for some guidance
    • MikeHerp
      This is no great surprise that HSV is pushed back in ExcisionBio's pipeline.  I'd be surprised if it isn't pushed back again. The chart they put out is painfully uninformative.  Sloppy.  And that's a red flag in and of itself. My guess is that those arrows are progress rather than efficiency, but it's not completely clear.  But if a scientific company can't get this chart right, then I really wonder what other mistakes they are making. I don't have a ton of confidence in this.  But we'll see.  I'm glad that it seems they are trying to do something.  I think CRISPR could be a solution to HSV (some kind of solution).  But I question whether it will be ExcisionBio that makes it in the end.  
    • MikeHerp
      Good to know.  I don't think this is a listed company, but from what I've read, they've gotten decent funding.  Around $70 million.  Most of that probably won't go to HSV research, but it's good they have some money. By comparison, ExcisionBio has raised $10 million.
    • MikeHerp
      The fact that Admedus is farming this out, kind of tells you it's a long shot at best.  It's good that it hasn't been abandoned.  But I'm doubtful much will come of this.  But maybe new knowledge about what doesn't work will come, and that's always helpful.
×

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.